Peptide questions · Bofanglutide
How long does bofanglutide take to work?
Reviewed Evidence: ModeratePublished by PepVault
Bofanglutide’s onset is days–2 weeks, its peak effect comes at 52 weeks (phase 3 endpoint), and its typical duration is ongoing, by the library’s timeline (backed by moderate evidence).
The timeline’s basis: Phase 1 (Liu 2025, Diabetes Obes Metab), phase 2b (Ji 2026, Signal Transduct Target Ther; NCT06256562), Gan & Lee releases Jun-12-2026 (GRADUAL-1, US phase 2) and Nov-4-2026 (GRADUAL-3), registry records. Investigational.
Bofanglutide week by week
The library places five of its research notes on bofanglutide on the days they cover, from day 1 to day 364 and on: 5 on randomized trials.
Day 1 is the first day of a run. Each bar is one of the library’s research notes, placed on the days it covers.
| When | The note | Evidence |
|---|---|---|
| Days 1–28 (weeks 1–4) | Three milligrams, the first step | Randomized trial |
| Days 29–210 (weeks 5–30) | Twelve milligrams every two weeks | Randomized trial |
| Days 57–364 (weeks 9–52) | Twenty-four milligrams, a phase 3 dose | Randomized trial |
| Days 85–364 (weeks 13–52) | The top dose | Randomized trial |
| From day 365 on | One shot a month to hold it | Randomized trial |

Model. Individual results vary.
The bofanglutide timeline’s milestones
The library’s timeline for bofanglutide marks 5 points from week 1 to week 76, backed by moderate evidence overall.
- Week 1: Commonly reported: appetite dropping in the first days on 3 mg
- Week 2: Its trials stepped the dose up every 2 to 4 weeks from 3 mg
- Week 30: Phase 2b endpoint: about 10% (12 mg) to 16% (48 mg) average loss every 2 weeks vs about 1% on placebo
- Week 52: Phase 3 GRADUAL-1: about 15% (24 mg) and 18.5% (48 mg) vs about 1% on placebo
- Week 76: GRADUAL-3: after the switch to one shot a month, weight held for 24 weeks
The weeks are the library’s reference timeline from studies and reported use, not a promise of what any one person will notice.
Why bofanglutide takes that long
Bofanglutide’s half-life is about 7 days (168 hours), so one dose is about 96.9% cleared after 35 days.
The library’s frequency for bofanglutide (“Every 2 weeks (or weekly)”) isn’t one fixed interval, so this page computes no build-up for it.
The notes on bofanglutide follow the trials’ dose steps, 3mg, 12mg, 24mg and 48mg, so the later weeks also describe higher steps than the first ones; these are steps from studies, not a schedule for a person.
Bofanglutide against other metabolic & GLP-1 compounds
The library holds an onset-and-peak timeline for 25 metabolic & GLP-1 compounds, bofanglutide among them; 17 of the others share its onset of days–2 weeks.
| Compound | Onset | Peak effect |
|---|---|---|
| Semaglutide | Days–2 weeks | 60–68 weeks |
| Tirzepatide | Days–2 weeks | 72+ weeks |
| Retatrutide | Days–2 weeks | 48+ weeks |
| Dulaglutide | Days–2 weeks | 24–52 weeks (glucose) |
| Exenatide | First dose (after-meal glucose) | 24–30 weeks (HbA1c) |
| Setmelanotide | 1–2 weeks (hunger) | 52 weeks (BMI) |
| Orforglipron | Days–2 weeks | 72 weeks (trial endpoint) |
| Survodutide | Days–2 weeks | 76 weeks (trial endpoint) |
| Mazdutide | Days–2 weeks | 48–60 weeks |
| Pemvidutide | Days–2 weeks | 48+ weeks |
| Cagrilintide | Days–2 weeks | 26–68 weeks (trial endpoints) |
| Pramlintide | First meal (fullness, after-meal glucose) | 16–52 weeks (weight, HbA1c) |
| CagriSema | Days–2 weeks | 68+ weeks |
| Eloralintide | Days–2 weeks | 48 weeks (phase 2 endpoint) |
| Petrelintide | Days–2 weeks | 42 weeks (phase 2, still falling) |
| Amycretin | Days–2 weeks | 36 weeks (longest trial so far) |
| MariTide | Days–2 weeks | 52 weeks (phase 2 endpoint, no plateau yet) |
| VK2735 | Days–2 weeks | 78 weeks (phase 3 endpoint, not yet read out) |
| Enicepatide | Days–2 weeks | 48 weeks (phase 2 endpoint, no plateau) |
| Ecnoglutide | Days–2 weeks | 48 weeks (phase 3, no plateau) |
| Bofanglutide | Days–2 weeks | 52 weeks (phase 3 endpoint) |
| Efinopegdutide | Weeks | 24–52 weeks (trial endpoints) |
| SLU-PP-332 | Unknown in people | Unknown in people |
| L-Carnitine (injectable) | Hours (blood levels rise) | 12–24 weeks (muscle carnitine, in the one long trial) |
| Tesofensine | 1–2 weeks (appetite falls) | 12–24 weeks (weight loss in the trial) |
Questions people ask
How long does bofanglutide take to work?
Bofanglutide’s onset is days–2 weeks, its peak effect comes at 52 weeks (phase 3 endpoint), and its typical duration is ongoing, by the library’s timeline (backed by moderate evidence).
When does bofanglutide reach its peak effect?
By the library’s timeline, bofanglutide’s peak effect comes at 52 weeks (phase 3 endpoint), backed by moderate evidence.
How long is bofanglutide usually run?
The library’s timeline gives bofanglutide’s typical duration as ongoing; its cycle note says: Used continuously in its trials: every 2 weeks for 30 to 52 weeks, with steps every 2 to 4 weeks.
What does the library say about the first days on bofanglutide?
Its first note on bofanglutide, for days 1–28 (weeks 1–4), is “Three milligrams, the first step”, resting on randomized trials.